CPI-613 is used as an inhibitor of mitochondrial tricarboxylic acid (TCA) for cancer treatment, because it can specifically target pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (α-KGDH) involved in the TCA cycle [11, 12]. This evidence concerns the gene OGDH and cancer.